BCL2 and acute myeloid leukemia: Indeed, the ex vivo treatment of clinical AML samples demonstrated synergy between azacitidine (AZA) and VEN at low nanomolar concentrations [13,26,27], and the combination of AZA with BCL2 inhibition was shown to synergistically induce the apoptosis of AML cells [28].